Compare FBRT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBRT | CGEM |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | 223 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 701.9M | 904.7M |
| IPO Year | N/A | 2020 |
| Metric | FBRT | CGEM |
|---|---|---|
| Price | $8.52 | $13.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $11.50 | ★ $30.13 |
| AVG Volume (30 Days) | 736.9K | ★ 881.8K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 15.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.34 | N/A |
| Revenue Next Year | $4.95 | $5.20 |
| P/E Ratio | $13.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.24 | $5.68 |
| 52 Week High | $11.84 | $16.74 |
| Indicator | FBRT | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 37.71 | 42.75 |
| Support Level | $8.38 | $12.41 |
| Resistance Level | $9.26 | $16.21 |
| Average True Range (ATR) | 0.21 | 0.94 |
| MACD | -0.06 | -0.16 |
| Stochastic Oscillator | 6.83 | 11.57 |
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. The Company's operations are organized into two business units: (i) Commercial Real Estate Financing, and (ii) Agency Business. Its four reporting segments are as follows: The real estate debt business, The Agency Business, The commercial real estate conduit business, and The real estate owned business.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.